Winton Group’s Aimmune Therapeutics AIMT Stock Holding History

Winton Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-57,453	Closed	-$1.98M	–	1615
2020 Q3	$1.98M	Buy	57,453 +43,856	+323%	+$934K	0.06%	533
2020 Q2	$227K	Buy	+13,597	New	+$231K	0.01%	1334
2019 Q4	–	Sell	-33,323	Closed	-$698K	–	1858
2019 Q3	$698K	Buy	+33,323	New	+$680K	0.01%	976
2018 Q2	–	Sell	-8,228	Closed	-$262K	–	1209
2018 Q1	$262K	Buy	+8,228	New	+$290K	0.01%	1032

Winton Group's AIMT Position: Q4 2020 in Review

Winton Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 57,453 shares — an estimated $1.98M sold.

Winton Group first reported a position in AIMT in Q1 2018 and held it in 4 quarters. The position peaked at $1.98M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Winton Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Winton Group sold 57,453 Aimmune Therapeutics shares in Q4 2020, an estimated $1.98M.
Winton Group first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 4 quarters.
Winton Group's Aimmune Therapeutics position peaked at $1.98M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.